Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
600 participants
OBSERVATIONAL
2013-12-31
2031-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The secondary objectives are:
* To validate emerging signatures/biomarkers identified.
* To develop new assays for the breast cancer clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TAILORx ICORG 06-31
Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with adequate tumor tissue available
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Trials Ireland
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bons Secours Hospital
Cork, , Ireland
Cork University Hospital
Cork, , Ireland
Letterkenny General Hospital
Donegal, , Ireland
Adelaide and Meath National Children's Hospital Tallaght
Dublin, , Ireland
St Vincent Universtiy Hospital
Dublin, , Ireland
St James Hospital
Dublin, , Ireland
Beaumont Hospital
Dublin, , Ireland
Mater Misericordiae University Hospital
Dublin, , Ireland
Galway University Hospital
Galway, , Ireland
Midwestern Regional Hospital
Limerick, , Ireland
Sligo General Hosptial
Sligo, , Ireland
Waterford Regional Hospital
Waterford, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lynch SM, Russell NM, Barron S, Wang CA, Loughman T, Dynoodt P, Fender B, Lopez-Ruiz C, O'Grady A, Sheehan KM, Fay J, Amberger-Murphy V, Saha A, Klinger R, Gonzalez CA, Al-Attar N, Rahman A, O'Leary D, Lanigan FT, Bracken AP, Crown J, Kelly CM, O'Connor DP, Gallagher WM. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. Eur J Cancer. 2021 Jul;152:78-89. doi: 10.1016/j.ejca.2021.04.016. Epub 2021 Jun 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICORG 12-30
Identifier Type: -
Identifier Source: org_study_id